Ticker Symbol: AUTL
Autolus Therapeutics plc - ADR
$7.00 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
United Kingdom
Currency:
USD
Asset
Type: ADR
CIK:0001730463
Company Profile
autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a leading biotechnology company focussed on the development and commercialisation of engineered t-cell therapies for haematological and solid tumours. autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient’s own cells.
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: Scale Space Building
Website: https://www.autolus.com/
CEO: N/A
Tags:
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Pricing
Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $2.56
Change:
$0.06
(
2.40%)
Days Range: $2.31 - $2.56
Beta: 0.84
52wk. High: $3.53
52wk. Low: $1.60
Ytd. Change 37.14%
50 Day Moving Average: $2.59
200 Day Moving Average: $2.59
Shares Outstanding: 173680872
Valuation
Market Cap: 44.5B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A